Copy Link Print Information

JNK-IN-8

(Synonyms: JNK Inhibitor XVI)
59 Cited Publications
Customer Review

Based on 59 publication(s) in Google Scholar

JNK-IN-8 (JNK Inhibitor XVI) is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.

For research use only. We do not sell to patients.

  • Purity: 99.67%
  • CAS No.: 1410880-22-6
  • Formula: C29H29N7O2
  • Molecular Weight:507.59
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • JNK-IN-8 Chemical Structure
    JNK-IN-8 Chemical Structure
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
  • Experimental Validation Results for JNK-IN-8
CAS No.: 1410880-22-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of JNK-IN-8:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) JNK-IN-8

More
Customer Validation & Images
Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIFCell Imaging/StainingRT-PCRFlow CytometryWB
  • In Vivo Efficacy Study
  • RT-PCR
  • Flow Cytometry
  • Flow Cytometry
  • IF
  • Cell Imaging/Staining
  • Cell Proliferation/Viability Assay
  • WB
  • WB

All JNK Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • JNK-IN-8 Chemical Structure
    JNK-IN-8 Chemical Structure
    1/16
  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 21;15(1):10106. [Abstract]

    Customer Validation
     p, q. Mice were treated with JNK-IN-8 (10 mg/kg, i.p., every other day for 15 days) inhibits NF2 LOF mutants-induced IOMM-Lee xenograft tumor growth. The collected tumors treated with DMSO or JNK-IN-8 were shown (p) and tumor weight was measured and quantified (mean ± s.d., n = 6 mice per group) (q).

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 7;16(1):1429. [Abstract]

    Customer Validation
     g-j. The effects of JNK (JNK-IN-8) (25 nM) and PKC (Go 6983) (100 nM) inhibition on the expression of Cxcl10 and Ccl4 in MC38 and Panc02 cells.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 7;16(1):1429. [Abstract]

    Customer Validation
     FACS analysis of CD8+ T-cell proliferation (CFSE low) in cultured with conditioned media derived from MC38 cells treated with WNT11 and inhibitors of CAMKII (CAMKII-IN-1) (100 nM), JNK (JNK-IN-8) (25 nM) and PKC (Go 6983) (100 nM) as indicated.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Oct 28;22(1):246. [Abstract]

    Customer Validation
     (K–N) Flow cytometry analysis of IFN-γ and T-bet expression in CD4+ T cells cultured under pTh17 conditions with or without JNK inhibitor (JNK-IN-8) ( 1 μM; 4 days).

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jun 3;23(1):621. [Abstract]

    Customer Validation
     IF demonstrates K8 and p62 protein changes after DMSO and JNK-IN-8 ( 3 μM; 24 h) treatment based on JNK pathway activation. Image J software was used to calculate fuorescence intensity of K8 and p62 in each group, and the co-localization of K8 and p62 was expressed as the ratio of the fuorescence intensity of K8 to that of p62. Then 3 randomly selected horizons were analyzed for fuorescence intensity and statistics. Bar =100 μm.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jun 3;23(1):621. [Abstract]

    Customer Validation
     The damage of cells, lysosomes and mitochondria in the control group, the TNF-α combined with IFN-γ and TGF-β stimulation group (treated with DMSO), and the TNF-α combined with IFN-γ and TGF-β stimulation group (treated with JNK-IN-8（3 μM; 24 h）) was observed by TEM. Bar = 2 μm/500 μm.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2023 Jun 5;10(1):25. [Abstract]

    Customer Validation
     The proliferation ability of PC-3 cells transfected with shASPA and/or treated with JNK-IN-8 (2 μM; 0-5 d) was assessed using a CCK-8 assay.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 May 4;37(1):99. [Abstract]

    Customer Validation
     A co-inhibitor of JNK and integrin β obviously decreases phosphorylation levels of JNK and c-JUN and expression of LOXL2 as compared with JNK inhibitor alone or integrin β1 alone.

  • 1/16

    JNK-IN-8 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2014 Oct 17;289(42):28753-64. [Abstract]

    Customer Validation
     Effect of the JNK inhibitor (JNK IN 8) on the induction of MKP-1 and MKP-2. RAW264.7 cells are first pretreated with vehicle (DMSO), 3 μM JNK IN 8, 10 μM of U0126, or a combination of both JNK IN 8 and U0126, for 30 min, and then stimulated with LPS for 60 min. Representative images are shown in the panels.

  • JNK-IN-8